BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

UNCY

Unicycive Therapeutics, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$0
$1M$500000$0
Q3 ’22Q4 ’22Q2 ’23Q3 ’23Q4 ’23
Company filings · 10-K filed 31 Mar 2025 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$44M+97.9% year on year
$60M$40M$20M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 12 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$28M
$20M$0−$20M−$40M
Q4 ’22Q4 ’23Q3 ’24Q3 ’25Q2 ’26
Company filings · 10-Q filed 12 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty